BlackRock’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-311,394
| Closed | -$1.41M | – | 5535 |
|
|
2025
Q3 | $1.41M | Sell |
311,394
-103,091
| -25% | -$304K | ﹤0.01% | 4197 |
|
|
2025
Q2 | $891K | Sell |
414,485
-1,012,370
| -71% | -$2.83M | ﹤0.01% | 4288 |
|
|
2025
Q1 | $6.24M | Sell |
1,426,855
-58,427
| -4% | -$263K | ﹤0.01% | 3550 |
|
|
2024
Q4 | $6.94M | Sell |
1,485,282
-5,427
| -0.4% | -$36.5K | ﹤0.01% | 3594 |
|
|
2024
Q3 | $10.5M | Buy |
1,490,709
+81,268
| +6% | +$590K | ﹤0.01% | 3383 |
|
|
2024
Q2 | $9.67M | Buy |
1,409,441
+1,092,991
| +345% | +$10.2M | ﹤0.01% | 3405 |
|
|
2024
Q1 | $4.47M | Buy |
316,450
+176,332
| +126% | +$2.68M | ﹤0.01% | 3718 |
|
|
2023
Q4 | $1.05M | Sell |
140,118
-11
| -0% | -$100 | ﹤0.01% | 4234 |
|
|
2023
Q3 | $2.1M | Sell |
140,129
-232
| -0.2% | -$4.17K | ﹤0.01% | 3976 |
|
|
2023
Q2 | $2.23M | Sell |
140,361
-63,394
| -31% | -$667K | ﹤0.01% | 4013 |
|
|
2023
Q1 | $1.46M | Sell |
203,755
-35,726
| -15% | -$253K | ﹤0.01% | 4194 |
|
|
2022
Q4 | $1.39M | Sell |
239,481
-80,392
| -25% | -$610K | ﹤0.01% | 4289 |
|
|
2022
Q3 | $3.04M | Sell |
319,873
-12,511
| -4% | -$164K | ﹤0.01% | 3979 |
|
|
2022
Q2 | $3.99M | Sell |
332,384
-399,170
| -55% | -$4.18M | ﹤0.01% | 3923 |
|
|
2022
Q1 | $9.58M | Sell |
731,554
-3,128
| -0.4% | -$45.8K | ﹤0.01% | 3597 |
|
|
2021
Q4 | $12.9M | Sell |
734,682
-8,825
| -1% | -$177K | ﹤0.01% | 3519 |
|
|
2021
Q3 | $16.1M | Sell |
743,507
-54,805
| -7% | -$1.4M | ﹤0.01% | 3423 |
|
|
2021
Q2 | $27.9M | Buy |
798,312
+75,963
| +11% | +$4.09M | ﹤0.01% | 3096 |
|
|
2021
Q1 | $71.2M | Buy |
722,349
+18,072
| +3% | +$2.17M | ﹤0.01% | 2389 |
|
|
2020
Q4 | $76.3M | Buy |
704,277
+24,062
| +4% | +$2.98M | ﹤0.01% | 2236 |
|
|
2020
Q3 | $70.1M | Buy |
680,215
+89,147
| +15% | +$13.4M | ﹤0.01% | 2099 |
|
|
2020
Q2 | $123M | Buy |
591,068
+86,615
| +17% | +$15.3M | ﹤0.01% | 1710 |
|
|
2020
Q1 | $49.3M | Buy |
504,453
+52,610
| +12% | +$6.13M | ﹤0.01% | 2053 |
|
|
2019
Q4 | $52.1M | Buy |
451,843
+11,192
| +3% | +$986K | ﹤0.01% | 2334 |
|
|
2019
Q3 | $24M | Buy |
440,651
+10,737
| +2% | +$1.21M | ﹤0.01% | 2713 |
|
|
2019
Q2 | $51.1M | Sell |
429,914
-2,053
| -0.5% | -$170K | ﹤0.01% | 2301 |
|
|
2019
Q1 | $22.6M | Sell |
431,967
-12,430
| -3% | -$502K | ﹤0.01% | 2684 |
|
|
2018
Q4 | $14M | Buy |
444,397
+75,373
| +20% | +$3.07M | ﹤0.01% | 2918 |
|
|
2018
Q3 | $22.3M | Buy |
369,024
+38,279
| +12% | +$2.15M | ﹤0.01% | 2810 |
|
|
2018
Q2 | $17.5M | Buy |
330,745
+261,466
| +377% | +$15.7M | ﹤0.01% | 2940 |
|
|
2018
Q1 | $4.02M | Buy |
69,279
+29,397
| +74% | +$1.83M | ﹤0.01% | 3484 |
|
|
2017
Q4 | $1.4M | Buy |
39,882
+361
| +0.9% | +$11.9K | ﹤0.01% | 3806 |
|
|
2017
Q3 | $1.44M | Buy |
39,521
+5,724
| +17% | +$159K | ﹤0.01% | 3792 |
|
|
2017
Q2 | $845K | Sell |
33,797
-106,850
| -76% | -$2.92M | ﹤0.01% | 3886 |
|
|
2017
Q1 | $3.8M | Buy |
140,647
+140,118
| +26,487% | +$3.99M | ﹤0.01% | 3470 |
|
|
2016
Q4 | $16K | Sell |
529
-16
| -3% | -$523 | ﹤0.01% | 3299 |
|
|
2016
Q3 | $23K | Buy |
545
+100
| +22% | +$3.79K | ﹤0.01% | 3244 |
|
|
2016
Q2 | $14K | Buy |
445
+331
| +290% | +$15K | ﹤0.01% | 3344 |
|
|
2016
Q1 | $5K | Buy |
114
+27
| +31% | +$1.51K | ﹤0.01% | 3368 |
|
|
2015
Q4 | $8K | Buy |
87
+71
| +444% | +$6.24K | ﹤0.01% | 2964 |
|
|
2015
Q3 | $1K | Hold |
16
| – | – | ﹤0.01% | 3184 |
|
|
2015
Q2 | $3K | Sell |
16
-4
| -20% | -$1.35K | ﹤0.01% | 3183 |
|
|
2015
Q1 | $8K | Hold |
20
| – | – | ﹤0.01% | 2826 |
|
|
2014
Q4 | $11K | Hold |
20
| – | – | ﹤0.01% | 2691 |
|
|
2014
Q3 | $7K | Buy |
+20
| New | +$5.95K | ﹤0.01% | 2918 |
|
BlackRock's ADVM Position: Q4 2025 in Review
BlackRock sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 311,394 shares — an estimated $1.41M sold.
BlackRock first reported a position in ADVM in Q3 2014 and held it in 45 quarters. The position peaked at $123M in Q2 2020. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.
- BlackRock reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
- BlackRock sold 311,394 Adverum Biotechnologies shares in Q4 2025, an estimated $1.41M.
- BlackRock first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 45 quarters.
- BlackRock's Adverum Biotechnologies position peaked at $123M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.
Based on BlackRock's 13F filing for Q4 2025, filed 12 Feb 2026.